Charles River Laboratories Announces CEO Succession Plan as Jim Foster Retires After 50-Year Career
核心洞察
Charles River Laboratories announced that CEO James C. Foster (搜索) will retire in May 2026 after a distinguished 50-year career, during which he transformed the company from a niche research models business to a global leader in preclinical drug development with approximately $4 billion in annual revenue.
The Board of Directors unanimously appointed Birgit Girshick (搜索), current Executive Vice President and COO, as the next CEO effective May 2026, following a comprehensive succession planning process designed to ensure continuity and strategic alignment.
Under Foster's leadership, Charles River completed over 50 acquisitions, achieved S&P 500 status in 2021, and worked on more than 80% of drugs approved by the FDA since 2017, with stock price appreciation exceeding 10% compound annual growth rate since its 2000 IPO.
Charles River Laboratories International announced a major leadership transition as James C. Foster (搜索), the company's Chair, President, and CEO, plans to retire on May 5, 2026, concluding a remarkable 50-year career with the preclinical contract research organization. The Board of Directors has unanimously appointed Birgit Girshick (搜索), current Executive Vice President and Chief Operating Officer, as the next CEO, effective concurrent with Foster's retirement.
Transformational Leadership Legacy
Foster's tenure represents one of the most significant transformations in the contract research industry. Under his leadership spanning more than 30 years as CEO, Charles River evolved from a niche research models business to the global leader in preclinical drug development, achieving approximately $4 billion in annual revenue and earning membership in the S&P 500 in 2021.
"As the visionary leader of the Company for more than 30 years as CEO, Jim Foster has transformed Charles River from a niche research models business to the global leader in preclinical drug development and respected member of the S&P 500," said Dr. Martin Mackay (搜索), Lead Independent Director, who will become Chair of the Board following the 2026 Annual Meeting.
The company's growth trajectory under Foster's leadership has been remarkable. Since its initial public offering in 2000, Charles River's stock price has appreciated at a compound annual growth rate of over 10%, while annual revenue increased from $307 million in 2000 to $4.0 billion in 2024. The company has completed more than 50 acquisitions during this period, fundamentally reshaping its business model with over 80% of revenue now generated from services.
Strategic Impact on Drug Development
Charles River's influence on the pharmaceutical industry has grown substantially under Foster's leadership. The company has worked on an average of more than 80% of the drugs approved by the U.S. Food and Drug Administration (搜索) since 2017, demonstrating its central role in the drug development ecosystem.
Foster began his career at Charles River in 1976 as General Counsel and held various senior positions before being named President in 1991, CEO in 1992, and Chair of the Board in 2000. He led a leveraged buyout by the Charles River management team from Bausch & Lomb in 1999, followed by the company's public offering on the NYSE in 2000. His entrepreneurial leadership was recognized when Forbes Magazine named him "Entrepreneur of the Year" in 2002.
Comprehensive Succession Planning
The leadership transition reflects years of strategic planning by the Board. Girshick, who has spent more than 35 years at Charles River, has served as COO since 2021, overseeing the company's global business units, strategic direction, operational excellence, and digital transformation initiatives.
"This CEO succession has been well planned for several years, as I did not take my decision to retire lightly, particularly at a time when our industry is evolving rapidly, the global regulatory environment is increasingly complex, and Charles River is at an inflection point," Foster commented. "I have been working closely with Birgit Girshick (搜索) for many years and entrusted her with roles of increasing responsibility."
Girshick's Extensive Experience
Girshick's career at Charles River spans multiple business units and leadership roles. She joined the company in 1989 and has held positions of increasing responsibility, beginning in the Research Models & Services and Avian Vaccine Services businesses. Her progression included roles as General Manager of Avian Vaccine Services in 2004, Corporate Vice President of Global Biopharmaceutical Services in 2010, and Corporate Executive Vice President overseeing multiple business units in 2018.
As COO since 2021, Girshick has been responsible for leading the company's global business units, guiding strategic direction, driving operational excellence and growth, maintaining client relationships, leading digital transformation, and integrating acquisitions. She holds a B.A. from Eastern Connecticut State University, an M.B.A. from the University of Rhode Island, and completed the Advanced Management Program at MIT's Sloan School of Management.
Enhanced Corporate Governance
The succession plan will implement enhanced corporate governance practices by separating the Chair and CEO roles. Foster will remain on the Board as a non-executive Director, while Dr. Martin Mackay (搜索), current Lead Independent Director, will become Chair of the Board. This structure aligns with best practices for corporate governance and oversight, including having a non-executive, independent Chairperson.
"The Board is confident that she is the right leader to drive forward the Company's strategic direction, future growth, and operational excellence for many years to come," Mackay stated regarding Girshick's appointment.
Strategic Focus for the Future
Girshick outlined her strategic priorities for Charles River's next chapter, emphasizing continued innovation and operational efficiency. "As we continue to move Charles River forward with our seasoned, global team, I am committed to building upon the solid foundation that Jim has established by leveraging the unique opportunities present in the evolving biopharmaceutical landscape," she said.
Her strategic focus includes enhancing the company's market-leading portfolio to drive top-line growth, maximizing financial performance, and maintaining a disciplined approach to capital deployment. The leadership transition occurs as Charles River continues to play an increasingly important role in accelerating drug development for pharmaceutical and biotechnology companies globally.
The planned transition in May 2026 represents a carefully orchestrated succession designed to maintain Charles River's position as the leading global preclinical contract research organization while positioning the company for continued growth in an evolving biopharmaceutical landscape.